Patents by Inventor Michael Ahlijanian

Michael Ahlijanian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF HUMANIZED CONFORMATION-SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
    Publication number: 20230287093
    Abstract: The present disclosure relates generally to conformation-specific antibodies that can bind to and neutralize the activity of phosphorylated-Threonine 231-tau protein (pT231-tau). The antibodies of the present technology are useful in methods for treating a neurological disorder associated with elevated cis-pT231-tau protein expression in a subject in need thereof.
    Type: Application
    Filed: January 17, 2023
    Publication date: September 14, 2023
    Applicant: Pinteon Therapeutics Inc.
    Inventors: Shankar Kumar, Naoya Tsurushita, Michael Ahlijanian, Martin Jefson
  • Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
    Patent number: 11591385
    Abstract: The present disclosure relates generally to conformation-specific antibodies that can bind to and neutralize the activity of phosphorylated-Threonine 231-tau protein (pT231-tau). The antibodies of the present technology are useful in methods for treating a neurological disorder associated with elevated cis-pT231-tau protein expression in a subject in need thereof.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: February 28, 2023
    Assignee: Pinteon Therapeutics Inc.
    Inventors: Shankar Kumar, Naoya Tsurushita, Michael Ahlijanian, Martin Jefson
  • METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF HUMANIZED CONFORMATION-SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
    Publication number: 20200362022
    Abstract: The present disclosure relates generally to conformation-specific antibodies that can bind to and neutralize the activity of phosphorylated-Threonine 231-tau protein (pT231-tau). The antibodies of the present technology are useful in methods for treating a neurological disorder associated with elevated cis-pT231-tau protein expression in a subject in need thereof.
    Type: Application
    Filed: November 8, 2018
    Publication date: November 19, 2020
    Applicant: Pinteon Therapeutics Inc.
    Inventors: Shankar KUMAR, Naoya Tsurushita, Michael Ahlijanian, Martin JEFSON
  • Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
    Publication number: 20060194825
    Abstract: Compounds which have utility in the treatment of conditions associated with altered mitochondrial function. The compounds having structure (I), including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.
    Type: Application
    Filed: December 19, 2003
    Publication date: August 31, 2006
    Applicant: MIGENIX Corp.
    Inventors: Soumitra Ghosh, Yazhong Pei, Xiao-Qing Tang, Spiros Liras, Michael Ahlijanian
  • Imidazole derivatives
    Publication number: 20060149066
    Abstract: The invention provides compounds of formula 1 wherein R1, R2, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission.
    Type: Application
    Filed: February 24, 2006
    Publication date: July 6, 2006
    Inventors: Mark Sanner, Chris Helal, Christopher Cooper, Frank Menniti, Patricia Seymour, Michael Ahlijanian, Anabella Villalobos, Lit-Fui Lau
  • Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto
    Publication number: 20060004093
    Abstract: Compounds which have utility in the treatment of conditions associated with altered mitochondrial function. The compounds have the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.
    Type: Application
    Filed: June 7, 2005
    Publication date: January 5, 2006
    Applicants: MIGENIX Corp., Pfizer Inc.
    Inventors: Soumitra Ghosh, Yazhong Pei, Xiao-Qing Tang, Spiros Liras, Michael Ahlijanian